| 1. |
- Albrechtsen, A., et al.
(author)
-
Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes
- 2013
-
In: Diabetologia. - : Springer Science and Business Media LLC. - 0012-186X .- 1432-0428. ; 56:2, s. 298-310
-
Journal article (peer-reviewed)abstract
- Human complex metabolic traits are in part regulated by genetic determinants. Here we applied exome sequencing to identify novel associations of coding polymorphisms at minor allele frequencies (MAFs) > 1% with common metabolic phenotypes. The study comprised three stages. We performed medium-depth (8x) whole exome sequencing in 1,000 cases with type 2 diabetes, BMI > 27.5 kg/m(2) and hypertension and in 1,000 controls (stage 1). We selected 16,192 polymorphisms nominally associated (p < 0.05) with case-control status, from four selected annotation categories or from loci reported to associate with metabolic traits. These variants were genotyped in 15,989 Danes to search for association with 12 metabolic phenotypes (stage 2). In stage 3, polymorphisms showing potential associations were genotyped in a further 63,896 Europeans. Exome sequencing identified 70,182 polymorphisms with MAF > 1%. In stage 2 we identified 51 potential associations with one or more of eight metabolic phenotypes covered by 45 unique polymorphisms. In meta-analyses of stage 2 and stage 3 results, we demonstrated robust associations for coding polymorphisms in CD300LG (fasting HDL-cholesterol: MAF 3.5%, p = 8.5 x 10(-14)), COBLL1 (type 2 diabetes: MAF 12.5%, OR 0.88, p = 1.2 x 10(-11)) and MACF1 (type 2 diabetes: MAF 23.4%, OR 1.10, p = 8.2 x 10(-10)). We applied exome sequencing as a basis for finding genetic determinants of metabolic traits and show the existence of low-frequency and common coding polymorphisms with impact on common metabolic traits. Based on our study, coding polymorphisms with MAF above 1% do not seem to have particularly high effect sizes on the measured metabolic traits.
|
|
| 2. |
|
|
| 3. |
- Lindqvist, Camilla, 1985, et al.
(author)
-
Fullerene Nucleating Agents: A Route Towards Thermally Stable Photovoltaic Blends
- 2014
-
In: Advanced Energy Materials. - : Wiley. - 1614-6840 .- 1614-6832. ; 4:9, s. 1301437-
-
Journal article (peer-reviewed)abstract
- The bulk-heterojunction nanostructure of non-crystalline polymer: fullerene blends has the tendency to rapidly coarsen when heated above its glass transition temperature, which represents an important degradation mechanism. We demonstrate that fullerene nucleating agents can be used to thermally arrest the nanostructure of photovoltaic blends that comprise a non-crystalline thiophene-quinoxaline copolymer and the widely used fullerene derivative [6,6]-phenyl-C-61-butyric acid methyl ester (PCBM). To this end, C-60 fullerene is employed to efficiently nucleate PCBM crystallization. Sub-micrometer-sized fullerene crystals are formed when as little as 2 wt% C-60 with respect to PCBM is added to the blend. These reach an average size of only 200 nanometers upon introduction of more than 8 wt% C-60. Solar cells based on C-60-nucleated blends indicate significantly improved thermal stability of the bulk-heterojunction nanostructure even after annealing at an elevated temperature of 130 degrees C, which lies above the glass transition temperature of the blend. Moreover, we find that various other compounds, including C-70 fullerene, single-walled carbon nanotubes, and sodium benzoate, as well as a number of commercial nucleating agents-commonly used to clarify isotactic polypropylene-permit to control crystallization of the fullerene phase.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Ferrari, Raffaele, et al.
(author)
-
Frontotemporal dementia and its subtypes: a genome-wide association study.
- 2014
-
In: Lancet Neurology. - 1474-4465. ; 13:7, s. 686-699
-
Journal article (peer-reviewed)abstract
- Frontotemporal dementia (FTD) is a complex disorder characterised by a broad range of clinical manifestations, differential pathological signatures, and genetic variability. Mutations in three genes-MAPT, GRN, and C9orf72-have been associated with FTD. We sought to identify novel genetic risk loci associated with the disorder.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
